Equity Overview
Price & Market Data
Price: $2.15
Daily Change: -$0.035 / 1.63%
Range: $2.10 - $2.24
Market Cap: $152,204,048
Volume: 300,966
Performance Metrics
1 Week: 20.57%
1 Month: 47.55%
3 Months: -16.60%
6 Months: -50.00%
1 Year: -71.45%
YTD: -15.26%
Company Details
Employees: 157
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.